News

05 Jul 2016
ReproCELL Group Establishes European Headquarters through Merger of Biopta and Reinnervate
Merger forms ReproCELL Europe Ltd, led by Dr David Bunton
Read more

13 May 2016
Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins
Proteon Therapeutics Inc., a collaborator of Biopta, today announced publication of additional nonclinical data on Vonapanitase, an investigational drug under development to improve Arteriovenous Fistula (AVF) maturation and patency in chronic kidney disease patients.
Read more

21 Apr 2016
Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase
Proteon Therapeutics Inc. a collaborator of Biopta, today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD).
Read more

More >

Testimonals

I am very pleased with our cooperation so far; nice data and very good fit to our internal knowledge of the compounds

Senior Scientist, Top 20 European Pharma

We used Biopta because they are able to provide sensitive and accurate information from a wide range of different types of tissue

CEO, UK Biotech

Biopta's human tissue services have played a critical part in our compound selection and have added considerable value to our lead compound

President & Head of R&D, Canadian Biotech
Live chat by BoldChat